5.4 Tobacco Use Disorder, Vaping & Cessation Interventions

5.4 Tobacco Use Disorder, Vaping & Cessation Interventions

Tobacco use disorder — including vaping and nicotine dependence — represents 5% of the CARN exam (approximately 7-9 items). Cigarette smoking remains the leading preventable cause of death in the United States (~480,000 deaths annually), and addictions nurses encounter nicotine dependence in nearly every treatment setting.

---

The Tobacco-SUD Intersection

Smoking prevalence among people with substance use disorders is 2 to 4 times higher than in the general population, with large majorities of patients in many addiction treatment samples smoking daily. Individuals in recovery from alcohol and opioid use disorders historically die more often from tobacco-related disease than from their primary substance.

Exam pearl: Delivering tobacco treatment during SUD treatment does not jeopardize sobriety. Integrated tobacco treatment is associated with improved long-term recovery outcomes, and modern addictions programs treat nicotine dependence concurrently rather than sequentially.

---

Nicotine Dependence and Withdrawal

Nicotine agonizes alpha-4 beta-2 nicotinic acetylcholine receptors, triggering mesolimbic dopamine release. Dependence is quantified with the Fagerström Test for Nicotine Dependence; its single most predictive item is time to first cigarette — smoking within 30 minutes of waking signals high dependence (and guides 4 mg gum/lozenge dosing). Cigarettes per day guides patch dosing (start 21 mg/day for ≥10 cigarettes/day).

Nicotine withdrawal produces irritability, anxiety, dysphoria, difficulty concentrating, increased appetite and weight gain, restlessness, and craving. Onset occurs within hours of the last cigarette, symptoms peak within 24-72 hours, and most physical symptoms wane over 2-4 weeks.

Nicotine Withdrawal Timeline (Patient Teaching)

1. 4-24 hours: craving onset, irritability, and anxiety begin as nicotine clears (half-life ~2 hours).
2. Days 1-3 (peak): strongest cravings, restlessness, poor concentration, increased appetite; most quit attempts fail here — pre-plan coping strategies and fast-acting NRT.
3. Weeks 2-4: physical symptoms subside; cue-triggered cravings (coffee, driving, stress) become the dominant relapse driver.
4. Months: weight gain and episodic cue-induced craving may persist; reinforce behavioral coping at every follow-up.

---

Health Consequences and Counseling Points

Tobacco drives cardiovascular disease, COPD, at least a dozen cancers, impaired wound and surgical healing, and adverse pregnancy outcomes; secondhand smoke harms children and household contacts. Counsel proactively about post-cessation weight gain (average 5-10 lb) — fear of weight gain deters quit attempts, so pair quit plans with nutrition and activity strategies rather than letting it become a barrier. Screen for all nicotine products individually: cigarettes, vaping, nicotine pouches, smokeless tobacco, cigars, and hookah — patients rarely volunteer non-cigarette use.

Behavioral Interventions and Systems Support

The 5 A's Model

1. Ask every patient about tobacco use at every visit (document as a vital sign).
2. Advise all users to quit with a clear, personalized, non-judgmental message.
3. Assess willingness to make a quit attempt within 30 days.
4. Assist with a quit plan: quit date, counseling, pharmacotherapy, social support.
5. Arrange follow-up within the first week after the quit date (relapse peak).

For patients unwilling to quit, use the 5 R's motivational intervention: Relevance, Risks, Rewards, Roadblocks, Repetition.

Systems resources include quitlines (1-800-QUIT-NOW), text-message programs, and digital apps. Combining behavioral counseling with medication roughly doubles quit rates over either alone. Every hospital admission is a cessation opportunity: treat inpatient nicotine withdrawal with NRT so patients can abstain comfortably during smoke-free stays.

---

Pharmacotherapy (Detailed in Section 4.4)

• Combination NRT (long-acting patch for baseline control plus short-acting gum/lozenge for breakthrough cravings) is the most effective over-the-counter approach.
• Varenicline (alpha-4 beta-2 partial agonist) is the most effective single agent; titrate over one week toward a Day-8 quit date.
• Bupropion SR is an alternative, contraindicated with seizure disorders, eating disorders, and abrupt alcohol/sedative withdrawal.

---

Vaping and E-Cigarettes

E-cigarettes deliver an aerosol, not 'water vapor,' containing nicotine salts at high concentrations, ultrafine particles, and flavoring chemicals. Youth use reached epidemic levels, and adolescent nicotine exposure harms the developing brain. EVALI (e-cigarette or vaping product use-associated lung injury), the 2019 outbreak of hypoxemic respiratory failure, was linked to vitamin E acetate used as a thickener in illicit THC vape cartridges. E-cigarettes are not FDA-approved cessation devices; counsel patients toward complete substitution with evidence-based therapy rather than dual use, and prioritize prevention messaging for adolescents.

---

Special Populations

• Pregnancy: behavioral counseling is first-line; NRT is considered when counseling fails, weighing risks against continued smoking.
• Adolescents: counseling-based approaches; no FDA-approved cessation medication under age 18.
• Psychiatric comorbidity: the large EAGLES trial found no increase in neuropsychiatric adverse events with varenicline or NRT in patients with stable psychiatric disorders — do not withhold effective cessation pharmacotherapy.